Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years

Clinical Pediatrics

Volumn 38, Issue 2, 1999, Pages 93-98

  Kafali, Gülden ^a,c   Erselcan, Taner ^b   Tanzer, Fatoş ^a  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Department of Nuclear Medicine ^*  (Turkey)

^c CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICONVULSANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; HUMAN; LUMBAR VERTEBRA; MALE; OSTEOPENIA; PHOSPHATE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0033045923     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992289903800205     Document Type: Article

References (20)

1. Hahn TJ, Hendin BA, Scharp CR, et al. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med. 1975;292:550-554.
2. Crosley CJ, Chre C, Berman PH. Rickets associated with long-term anticonvulsant therapy in a pediatric outpatient population. Pediatrics. 1975;56: 52-57.
3. Keck E, Gollnick B, Reinhardt D, et al. Calcium metabolism and vitamin D metabolite levels in children receiving anticonvulsant drugs. Eur J Pediatr. 1982;139:52-55.
4. 2 administration. Calcif Tissue Int. 1979;27:13-18.
5. Christiansen C, Rodbro P, Tjellesen L. Pathophysiology behind anticonvulsant osteomalacia. Acta Neurol Scand. 1983;94:21-28.
6. Ala-Houhala M, Korpela R, Koivikko M, et al. Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children. Neuropediatrics. 1986;17:212-216.
7. Fischer MH, Adkins WN, Liebl BH, et al. Bone status in nonambulant, epileptic, institutionalized youth. Clin Pediatr. 1988;27:499-505.
8. 3-activating cytochrome P-450-linked monooxygenase systems. J Steroid Biochem Mol Biol. 1991;39:479-485.
9. Lee JJ, Lyne ED, Kleerekoper M, et al. Disorders of bone metabolism in severely handicapped children and young adults. Clin Orthop. 1989;245: 297-302.
10. 3). Am J Dis Child. 1986;140:715-718.
11. Christiansen C, Rodbro P, Lund P. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J. 1973;4:695.
12. Duus BR. Fractures caused by epileptic seizures and epileptic osteomalacia. Injury. 1986;17:31-33.
13. Riggs BL, Melton LJI. Involutional osteoporosis. N Engl J Med. 1986;314: 1676-1686.
14. Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone. 1990;11:309-312.
15. Takeshita N, Seino Y, Ishida H, et al. Increased circulating levels of γ-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int. 1989;44:80-85.
16. Tjeilesen L, Nilas L, Christiensen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand. 1983;68:13-19.
17. Liakakos D, Papadopoulos Z, Viachos P, et al. Serum alkaline phosphatase and urinary hydroxyproline values in children receiving phenobarbital with and without vitamin D. J Pediatr. 1975; 87:291-296.
18. Winnacker JL, Yeager H, Saunders JA, et al. Rickets in children receiving anticonvulsant drugs: biochemical and hormonal markers. Am J Dis Child. 1977;131:286-290.
19. Kröger H, Kotaniemi A, Kröger L, Alhava E. Development of bone mass and bone density of the spine and femoral neck - a prospective study of 65 children and adolescents. Bone Miner. 1993;23:171-182.
20. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127:256-262.